BioAtla (BCAB) announced data in a poster titled, “Phase 2 Trial of Ozuriftamab Vedotin, a Conditionally Binding CAB-ROR2-ADC, in Patients with ...

the poster will be converted to a virtual abstract. To be eligible for participation, an applicant must be a currently enrolled medical student at Baylor College of Medicine (regular M.D. and dual M.D ...

Phase 2 survival and clinical benefit data meet or exceed outcomes of FDA-approved therapies in comparable metastatic breast ...

PDS Biotechnology ( ($PDSB) ) has shared an update. On June 2, 2025, PDS Biotechnology Corporation announced the publication of three Versamune® ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that it will present new sebetralstat data at two upcoming ...

SAN DIEGO, May 22, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it ...

Oncology specialists from UC San Francisco will present new clinical research findings and cutting-edge treatment strategies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...

The Infectious Disease Sciences Program of Fred Hutch is committed to investing in the future of infectious disease research and patient care. Therefore, we have implemented a program to assist ...

Please see the virtual presentation guidelines. Virtual presentations will be judged. Posters will not be judged. Virtual presentation abstracts must be submitted by April 1 at 11:59pm to be included ...